Our Mission

The V Foundation is a charitable organization dedicated to saving lives by helping to find a cure for cancer. The Foundation seeks to make a difference by generating broad-based support for cancer research and by creating an urgent awareness among all Americans of the importance of the war against cancer. The Foundation performs these dual roles through advocacy, education, fundraising, and philanthropy.
The V Foundation awards three types of grants. The V Scholar Grant provides funds directly to young scientists to establish their own independent laboratory. The Translational Grant facilitates the transition of projects from the laboratory to the clinic. The Designated Grant funds projects in communities or regions local to the fundraising area.

**2012 V SCHOLARS**

**Hiu Wing Cheung, Ph.D.**
Hollings Cancer Center  
Medical University of South Carolina  
Charleston, SC  
*Role of ID4 in ovarian cancer development and metastasis*

**Christina Curtis, Ph.D.**
USC Norris Comprehensive Cancer Center  
University of Southern California  
Los Angeles, CA  
*Interrogating patient-specific tumor dynamics through single cell profiles and computational modeling*

**Todd Fehniger, M.D., Ph.D.**
Siteman Cancer Center  
Washington University School of Medicine  
St. Louis, MO  
*Enhanced innate immunity to cancer utilizing human memory-like NK cells*

**Daniel A. Harki, Ph.D.**
Masonic Cancer Center  
University of Minnesota  
Minneapolis, MN  
*Funded by Delta Chi Fraternity  
Beyond parthenolide: next generation molecules targeting AML cancer stem cells*

**Justin D. Lathia, Ph.D.**
Cleveland Clinic Lerner College of Medicine  
Cleveland, OH  
*Albert Wyrick V Scholar Award  
Holding on to stemness: targeting mechanisms that maintain glioblastoma stem cells*

**Qing Li, M.D., Ph.D.**
University of Michigan Comprehensive Cancer Center  
University of Michigan  
Ann Arbor, MI  
*NRAS signaling in hematopoietic stem cells and leukemic stem cells*

**Unhee Lim, Ph.D.**
University of Hawaii Cancer Center  
Honolulu, HI  
*Investigating global leukocyte DNA methylation for predicting colorectal cancer risk in a multiethnic population*

**Mohammad (Mo) Motamedi, Ph.D.**
Massachusetts General Hospital Cancer Center  
Charlestown, MA  
*The role of sirtuins in epigenetics and genomic stability*

**Trudy G. Oliver, Ph.D.**
Huntsman Cancer Institute  
University of Utah  
Salt Lake City, UT  
*Funded by the Thomas Carroll Family  
In memory of Christopher T. Carroll  
Understanding Myc’s role in small cell lung cancer*

**Asha Bhaskaran Pillai, M.D.**
St. Jude Children’s Research Hospital  
Memphis, TN  
*Augmenting cytotoxicity of ex vivo expanded human iNKT cells for cancer immunotherapy*

**Jeffrey W. Tyner, Ph.D.**
Knight Cancer Institute  
Oregon Health and Science University  
Portland, OR  
*Translation of novel mutations in CSF3R into validated therapeutic modalities*

**Christopher R. Vakoc, M.D., Ph.D.**
Cold Spring Harbor Laboratory  
Cold Spring Harbory, NY  
*Therapeutic targeting of the polycomb complex PRC2 in acute myeloid leukemia*
Jeffrey Venstrom, M.D.
UCSF Helen Diller Family Comprehensive Cancer Center
University of California at San Francisco
San Francisco, CA
Funded by The V Foundation Wine Celebration Volunteer Grant
In honor of Derek and Cathy Reisinger
Mechanisms and strategies for recruiting natural killer cells to cure acute myeloid leukemia

Jessie Villanueva, Ph.D.
The Wistar Institute
Philadelphia, PA
Establishing molecular targets for NRAS driven melanomas: an unmet medical need

Sarah (Sadie) Wignall, Ph.D.
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL
Targeting centrosome-clustering mechanisms to selectively kill cancer cells

Monte M. Winslow, Ph.D.
Stanford Cancer Institute
Stanford University
Stanford, CA
Martin D. Abeoff, M.D. V Scholar Award*
Functional characterization of Nkx2-1 regulated genes that govern lung cancer metastasis

Xiaoyang Wu, Ph.D.
University of Chicago Comprehensive Cancer Institute
Chicago, IL
Spectraplakin and coordinated cytoskeletal dynamics in colorectal cancer

*The research project that receives the highest rating by the Scientific Advisory Board will annually be designated as the Martin D. Abeloff, M.D. V Scholar Award.

2012 TRANSLATIONAL GRANTS

Steven P. Balk, M.D., Ph.D.
Huihui Ye, MMSc.
Glenn Bubley, M.D.
Martin Sanda, M.D.
Beth Israel Deaconess Medical Center
Boston, MA
Molecular characterization of gleason 3 tumors that progress to gleason 4

Michele Carbone, M.D., Ph.D.
Haining Yang, Ph.D.
Ian Pagano, Ph.D.
University of Hawaii Cancer Center
Honolulu, HI
HMGB1: A biomarker for mineral fiber exposure and detection of malignant mesothelioma

Reuben S. Harris, Ph.D.
Douglas Yee, M.D.
Masonic Cancer Center
University of Minnesota
Minneapolis, MN
Funded by The V Foundation Wine Celebration Vintner Grant
In honor of Suzanne Pride-Bryan
Role of DNA deamination in breast cancer

Nora Heisterkamp, Ph.D.
Steven Mittelman, M.D., Ph.D.
Yong-mi Kim, M.D., Ph.D.
Children’s Hospital Los Angeles
Los Angeles, CA
Improving treatment outcome in leukemia by disruption of bone-marrow leukemia interactions relevant to minimal residual disease

Angela M. Hartley Brodie, Ph.D.
University of Maryland School of Medicine
Funded by Friends of V Baltimore Golf Classic
Targeting mechanisms of resistance to hormone therapy in breast cancer

Miaofen G. Hu, M.D., Ph.D.
Richard Van Eten, M.D., Ph.D.
Tufts Medical Center
Medford, MA
CDK6 as a novel therapeutic target in T-cell acute lymphoblastic leukemia

Mark C. Lanasa, M.D., Ph.D.
Sandeep Dave, M.D., M.S.
Duke Cancer Institute
Duke University Medical Center
Durham, NC
Genetic determinants of progression in chronic lymphocytic leukemia

Anthony E. Oro, M.D., Ph.D.
Jean Y. Tang, M.D., Ph.D.
Stanford Cancer Institute
Stanford University
Stanford, CA
Novel therapies for hedgehog-dependent cancers

W. Kimryn Rathmell, M.D., Ph.D.
Jason Lieb, Ph.D.
Ivan Davis, M.D., Ph.D.
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, NC
Funded by the Jimmy V Celebrity Golf Classic
In memory of Girard Tillery
Reprogramming the histone methylation code of renal cell carcinoma

Martine F. Roussel, Ph.D.
Amar Gajjar, M.D.
St. Jude Children’s Research Hospital
Memphis, TN
Identification and pre-clinical testing of compounds to treat group 3 medulloblastoma

W. Kimryn Rathmell, M.D., Ph.D.
Jason Lieb, Ph.D.
Ivan Davis, M.D., Ph.D.
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, NC
Funded by the Jimmy V Celebrity Golf Classic
In memory of Girard Tillery
Reprogramming the histone methylation code of renal cell carcinoma

Martine F. Roussel, Ph.D.
Amar Gajjar, M.D.
St. Jude Children’s Research Hospital
Memphis, TN
Identification and pre-clinical testing of compounds to treat group 3 medulloblastoma
Kimberly Stegmaier, M.D.
James E. Bradner, M.D.
Lisa R. Diller, M.D.
Dana-Farber Cancer Institute
Boston, MA
Therapeutic targeting of N-Myc with BET bromodomain inhibition in neuroblastoma

Corrine Linardic, M.D., Ph.D.
Duke Cancer Institute
Duke University Medical Center
Durham, NC
Funded by Apple Gold Group
Understanding SFRP’s contribution to alveolar rhabdomyosarcoma tumorigenesis

University of Texas MD Anderson Cancer Center
Pediatric Cancer
Funded by LG Electronics Home Court Advantage

Nehal Parikh, M.D.
Connecticut Children’s Medical Center
Hartford, CT
Funded by ESPN, Inc.
Isolation and characterization of cancer stem cells in neuroblastoma tumor model

St. Helena Hospital Foundation
St. Helena, CA
Funded by The V Foundation Wine Celebration

University of Texas MD Anderson Cancer Center
Houston, TX
SPORE in Ovarian Cancer
Funded by the Kay Yow Cancer Fund

Daniel S. Wechsler, M.D., Ph.D.
Duke Cancer Institute
Duke University Medical Center
Durham, NC
Funded by Apple Gold Group
Strike while the iron is not: targeting CALM-rearranged leukemias by iron deprivation

Hai Yan, M.D., Ph.D.
Duke Cancer Institute
Duke University Medical Center
Durham, NC
Supplemental SPORE
Funded by The V Foundation Wine Celebration and Accelerate Brain Cancer Cure
Developing novel approaches to target gliomas

Steven Zeitels, M.D., FACS
Massachusetts General Hospital Cancer Center
Boston, MA
Funded by the Dick Vitale Gala
Voice preservation in the treatment of early glottic (laryngeal) cancer

2012 DESIGNATED GRANTS

All Children’s Hospital
Dick Vitale Pediatric Cancer Research Fellowship
St. Petersburg, FL
Funded by the Dick Vitale Gala

Victoria F. Borges, M.D., MMSc
University of Colorado Cancer Center
Denver, CO
Funded by the Kay Yow Cancer Fund
Pilot study the prevention of postpartum pregnancy associated breast cancer

Ian Davis, M.D., Ph.D.
UNC Lineberger Comprehensive Cancer Center at UNC
Funded by the Jimmy V Celebrity Golf Classic
Targeting deregulated transcription in pediatric cancers

James M. Ford, M.D.
Stanford Cancer Institute
Stanford University
Palo Alto, CA
Funded by the Gastric Cancer Foundation

Peter Forsyth, M.D.
H. Lee Moffitt Cancer Center and Research Institute
University of South Florida
Tampa, FL
Funded by the Dick Vitale Gala
Developing myxoma virus as an experimental treatment for brain cancer stem cells in children and adults with malignant gliomas

Susan Goodin, PharmD.
Cancer Institute of New Jersey
Robert Wood Johnson Medical School
University Medical Center
New Brunswick, NJ
Funded by Marketing Research Consultants
Prevention of prostate cancer progression by atorvastatin and celecoxib

Ramaswamy Govindan, M.D.
Siteman Cancer Center
Washington University School of Medicine
St. Louis, MO
Funded by UNICO
In memory of Dorothy Jean Varsalona
Molecular assay to predict outcomes in resected NSCLC using nanostring technology
The V Foundation Board of Directors is entrusted with and accountable for the strategic leadership and governance of the organization. The Board is comprised of prominent business leaders, award-winning athletes and coaches, distinguished physicians and world-renowned entertainers. Their governance is integral to the sustainability and long-term effectiveness of the Foundation in ways that are consistent with our core values and principles.

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jim Allegro</td>
<td>Emeritus Director, Retired Executive Vice President</td>
<td>ESPN, Inc.</td>
</tr>
<tr>
<td>Julie Allegro</td>
<td>General Partner</td>
<td>Allegro Venture Partners</td>
</tr>
<tr>
<td>Robert C. Bast Jr., M.D.</td>
<td>Vice President for Translational Research</td>
<td>University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>George Bodenheimer</td>
<td>Executive Chairman</td>
<td>ESPN, Inc.</td>
</tr>
<tr>
<td>Steven M. Bornstein</td>
<td>President and Chief Executive Officer</td>
<td>NFL Network</td>
</tr>
<tr>
<td>Bill Cosby</td>
<td></td>
<td></td>
</tr>
<tr>
<td>George W. Dennis III</td>
<td>Retired Senior Partner</td>
<td>Teague Campbell Dennis &amp; Gorham, LLP</td>
</tr>
<tr>
<td>David B. Fay</td>
<td>Retired Executive Director</td>
<td>United States Golf Association</td>
</tr>
<tr>
<td>Rosa M. Gatti</td>
<td>Retired Senior Vice President, Communications Counsel and Corporate Outreach</td>
<td>ESPN, Inc.</td>
</tr>
<tr>
<td>Philip H. Knight</td>
<td>Chairman of the Board of Directors</td>
<td>Nike, Inc.</td>
</tr>
<tr>
<td>Michael W. Krzyzewski</td>
<td>Head Coach, Men’s Basketball</td>
<td>Duke University</td>
</tr>
<tr>
<td>Eric Lautenbach</td>
<td>Director of College Basketball Sports Marketing</td>
<td>NIKE, Inc.</td>
</tr>
<tr>
<td>Carl C. Liebert III</td>
<td>President</td>
<td>USAA Capital Corporation</td>
</tr>
<tr>
<td>Robert E. Lloyd</td>
<td>Chairman</td>
<td>The V Foundation for Cancer Research</td>
</tr>
<tr>
<td>Joe Loughrey</td>
<td>Retired President and Vice Chairman</td>
<td>Cummins, Inc.</td>
</tr>
<tr>
<td>Michael C. Mac Donald</td>
<td>Chairman and Chief Executive Officer</td>
<td>Medifast</td>
</tr>
<tr>
<td>Michael E. Marks</td>
<td>Founding Partner</td>
<td>Riverwood Capital, LLC</td>
</tr>
<tr>
<td>Geoffrey S. Mason</td>
<td>Senior Production Specialist</td>
<td>ESPN, Inc.</td>
</tr>
<tr>
<td>Name</td>
<td>Title/Role</td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Joseph O. Moore, M.D.</td>
<td>Medical Director, Duke Raleigh Cancer Center, Professor, Hematology &amp; Oncology, Duke Cancer Institute</td>
<td></td>
</tr>
<tr>
<td>Robert C. Nakasone</td>
<td>Retired Chief Executive Officer, Toys “R” Us</td>
<td></td>
</tr>
<tr>
<td>Donna Orender</td>
<td>Chief Executive Officer, Orender Unlimited LLC</td>
<td></td>
</tr>
<tr>
<td>Lawrence F. Probst III</td>
<td>Chairman of the Board, Electronic Arts, Chairman, United States Olympic Committee</td>
<td></td>
</tr>
<tr>
<td>Harry E. Rhoads, Jr.</td>
<td>Chief Executive Officer, Washington Speakers Bureau, Secretary, The V Foundation for Cancer Research</td>
<td></td>
</tr>
<tr>
<td>Robert Roberts</td>
<td>Co-Anchor, ABC’s Good Morning America</td>
<td></td>
</tr>
<tr>
<td>John P. Saunders</td>
<td>Sports Commentator, ESPN, Inc. and ABC Sports</td>
<td></td>
</tr>
<tr>
<td>Constance E. Skidmore</td>
<td>Former Board Member and Managing Partner, PricewaterhouseCoopers LLC</td>
<td></td>
</tr>
<tr>
<td>John Skipper</td>
<td>President, ESPN, Inc.</td>
<td></td>
</tr>
<tr>
<td>Anthony F. Smith, Ph.D.</td>
<td>Co-Founder and Managing Director, Leadership Research Institute</td>
<td></td>
</tr>
<tr>
<td>Pamela Valvano Strasser</td>
<td>Chairwoman, The V Foundation for Cancer Research</td>
<td></td>
</tr>
<tr>
<td>Nicholas P. Valvano</td>
<td>President Emeritus, The V Foundation for Cancer Research</td>
<td></td>
</tr>
<tr>
<td>Robert Valvano</td>
<td>Sports Commentator</td>
<td></td>
</tr>
<tr>
<td>Lesley Visser</td>
<td>Sports Commentator, CBS and HBO</td>
<td></td>
</tr>
<tr>
<td>Dick Vitale</td>
<td>Sports Commentator, ESPN, Inc. and ABC Sports</td>
<td></td>
</tr>
<tr>
<td>R.C. “Bucky” Waters</td>
<td>Retired Vice Chancellor/Special Projects, Duke University Medical Center, Sports Commentator, ESPN, Inc. &amp; Madison Square Garden</td>
<td></td>
</tr>
<tr>
<td>Robert P. Wayman</td>
<td>Retired Chief Financial Officer and Executive Vice President, Hewlett-Packard Company</td>
<td></td>
</tr>
<tr>
<td>Dereck Whittenburg</td>
<td>Sports Commentator, ESPN, Inc.</td>
<td></td>
</tr>
<tr>
<td>David W. Williams</td>
<td>Retired Senior Vice President, Whirlpool Corporation</td>
<td></td>
</tr>
<tr>
<td>Norby Williamson</td>
<td>Executive Vice President, Programming &amp; Acquisitions, ESPN, Inc.</td>
<td></td>
</tr>
<tr>
<td>Larry Woodard</td>
<td>President and Chief Executive Officer, Graham Stanley Advertising</td>
<td></td>
</tr>
</tbody>
</table>
The Scientific Advisory Board is comprised of leading physicians and research scientists from prominent universities and cancer centers. The all-volunteer Scientific Advisory Board ensures that grant proposals meet the highest standards of scientific merit and that funding is properly allocated.

Robert C. Bast, Jr., M.D.
Vice President for Translational Research
MD Anderson Cancer Center
Houston, TX

William T. Beck, Ph.D.
Professor and Head
Department of Biopharmaceutical Sciences
University of Illinois at Chicago
Chicago, IL

Gerold Bepler, M.D., Ph.D.
President & Chief Executive Officer
Karmanos Cancer Institute
Detroit, MI

Lisa M. Coussens, Ph.D.
Hildegard Lamfrom Chair in Basic Science
Professor and Chair, Cell & Developmental Biology
Associate Director for Basic Research
Knight Cancer Institute
Oregon Health & Science University
Portland, OR

Nancy E. Davidson, M.D.
Director
University of Pittsburgh Cancer Institute
Pittsburgh, PA

H. Shelton Earp III, M.D.
Director & Lineberger Professor
Professor of Medicine and Pharmacology
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Paul F. Engstrom, M.D.
Senior Vice President for Population Science
Fox Chase Cancer Center
Philadelphia, PA

Olivera J. Finn, Ph. D.
Professor & Chair, Dept. of Immunology
University of Pittsburgh School of Medicine
Pittsburgh, PA

Richard I. Fisher, M.D.
Physician-in-Chief & Executive Vice President
Fox Chase Cancer Center
Senior Associate Dean
Temple University School of Medicine
Philadelphia, PA

James M. Ford, M.D.
Associate Professor of Medicine and Genetics
Stanford University School of Medicine
Stanford, CA

Susan G. Hilsenbeck, Ph.D.
Fellow of the American Statistical Association
Vice Chair, Baylor College of Medicine Institutional Review Board
Baylor College of Medicine
Houston, TX

Theodore S. Lawrence, M.D., Ph.D.
Chair, Radiation Oncology
Co-Chair, Radiation Sciences Program
University of Michigan
Comprehensive Cancer Center
Ann Arbor, MI

A. Thomas Look, M.D.
Professor, Pediatrics
Harvard Medical School
Vice Chair, Pediatric Oncology Research
Dana-Farber Cancer Institute
Harvard Cancer Center Leukemia Program
Cambridge, MA

John D. Minna, M.D.
Professor and Director, Hamon Center for Therapeutic Oncology Research
Professor, Internal Medicine & Pharmacology
Director, Center for Cancer Genetics
University of Texas Southwestern Medical Center
Dallas, TX
THE V FOUNDATION SCIENTIFIC ADVISORY BOARD IS AN EXCEPTIONAL GROUP OF PHYSICIANS AND SCIENTISTS WHO ASSURE THAT FUNDS FROM DONORS ARE INVESTED WISELY IN THE CAREERS OF THE MOST GIFTED AND MOTIVATED YOUNG INVESTIGATORS AND IN THE MOST PROMISING PROJECTS WHICH MOVE NEW DRUGS AND APPROACHES FROM THE LABORATORY TO THE CLINIC.

— DR. ROBERT BAST
### STATEMENT OF FINANCIAL POSITION
September 30, 2012

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>LIABILITIES AND NET ASSETS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td>Current Liabilities</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>Accounts payable &amp; accrued expenses</td>
</tr>
<tr>
<td>Accounts receivable, net</td>
<td>Accrued payroll &amp; related liabilities</td>
</tr>
<tr>
<td>Promises to give, net</td>
<td>Lease payable</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>Grants payable</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT ASSETS</strong></td>
<td><strong>TOTAL CURRENT LIABILITIES</strong></td>
</tr>
<tr>
<td><strong>PROPERTY &amp; EQUIPMENT, NET</strong></td>
<td>Long-Term Liabilities</td>
</tr>
<tr>
<td>38,177</td>
<td>Grants payable, net</td>
</tr>
<tr>
<td><strong>OTHER ASSETS</strong></td>
<td><strong>TOTAL LIABILITIES</strong></td>
</tr>
<tr>
<td>Investments</td>
<td>21,026,926</td>
</tr>
<tr>
<td>Promises to give, net</td>
<td>3,874,888</td>
</tr>
<tr>
<td><strong>TOTAL OTHER ASSETS</strong></td>
<td><strong>TOTAL NET ASSETS</strong></td>
</tr>
<tr>
<td>24,901,814</td>
<td>24,901,814</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
</tr>
<tr>
<td>36,782,510</td>
<td>36,782,510</td>
</tr>
</tbody>
</table>

### STATEMENT OF ACTIVITIES & CHANGES IN NET ASSETS
For the Year Ended September 30, 2012

<table>
<thead>
<tr>
<th>SUPPORT AND REVENUE</th>
<th>UNRESTRICTED</th>
<th>TEMPORARILY RESTRICTED</th>
<th>PERMANENTLY RESTRICTED</th>
<th>TOTALS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions and gifts</td>
<td>$9,287,602</td>
<td>$936,206</td>
<td>$2,533,706</td>
<td>$12,757,514</td>
</tr>
<tr>
<td>Special events income, net of expenses</td>
<td>3,827,663</td>
<td>-</td>
<td>-</td>
<td>3,827,663</td>
</tr>
<tr>
<td>Investment income</td>
<td>138,643</td>
<td>322,984</td>
<td>-</td>
<td>461,627</td>
</tr>
<tr>
<td>Unrealized gain on investments</td>
<td>320,457</td>
<td>813,615</td>
<td>-</td>
<td>1,134,072</td>
</tr>
<tr>
<td>Realized gain on investments</td>
<td>112,857</td>
<td>286,511</td>
<td>-</td>
<td>399,368</td>
</tr>
<tr>
<td><strong>TOTAL SUPPORT AND REVENUE</strong></td>
<td>13,687,222</td>
<td>2,359,316</td>
<td>2,533,706</td>
<td>18,580,244</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>2,908,465</td>
<td>(2,908,465)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>TOTAL SUPPORT AND REVENUE</strong></td>
<td>16,595,687</td>
<td>(549,149)</td>
<td>2,533,706</td>
<td>18,580,244</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EXPENSES</th>
<th>UNRESTRICTED</th>
<th>TEMPORARILY RESTRICTED</th>
<th>PERMANENTLY RESTRICTED</th>
<th>TOTALS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td>15,537,636</td>
<td>-</td>
<td>-</td>
<td>15,537,636</td>
</tr>
<tr>
<td>SUPPORTING SERVICES</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management and general</td>
<td>724,916</td>
<td>-</td>
<td>-</td>
<td>724,916</td>
</tr>
<tr>
<td>Fundraising expenses</td>
<td>769,755</td>
<td>-</td>
<td>-</td>
<td>769,755</td>
</tr>
<tr>
<td><strong>TOTAL SUPPORTING SERVICES</strong></td>
<td>1,494,671</td>
<td>-</td>
<td>-</td>
<td>1,494,671</td>
</tr>
<tr>
<td><strong>SUBTOTAL EXPENSES</strong></td>
<td>17,032,307</td>
<td>-</td>
<td>-</td>
<td>17,032,307</td>
</tr>
<tr>
<td>Loss from bad debts</td>
<td>-</td>
<td>150,000</td>
<td>80,000</td>
<td>230,000</td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td>17,032,307</td>
<td>150,000</td>
<td>80,000</td>
<td>17,262,307</td>
</tr>
<tr>
<td><strong>CHANGES IN NET ASSETS</strong></td>
<td>(436,620)</td>
<td>(699,149)</td>
<td>2,453,706</td>
<td>1,317,937</td>
</tr>
<tr>
<td><strong>NET ASSETS - BEGINNING OF YEAR</strong></td>
<td>(2,770,420)</td>
<td>4,533,875</td>
<td>13,302,406</td>
<td>15,065,861</td>
</tr>
<tr>
<td><strong>NET ASSETS - END OF YEAR</strong></td>
<td>($3,207,040)</td>
<td>$3,834,726</td>
<td>$15,756,112</td>
<td>$16,383,798</td>
</tr>
</tbody>
</table>
### GRANT DISTRIBUTIONS BY CANCER SITE, 1994-2012

<table>
<thead>
<tr>
<th>Grants</th>
<th>Cancer Site</th>
<th>Funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>176</td>
<td>General Cancer/Other</td>
<td>$21,393,992</td>
</tr>
<tr>
<td>66</td>
<td>Leukemia/Lymphoma</td>
<td>$17,375,000</td>
</tr>
<tr>
<td>53</td>
<td>Breast</td>
<td>$10,515,000</td>
</tr>
<tr>
<td>45</td>
<td>Pediatric</td>
<td>$13,159,000</td>
</tr>
<tr>
<td>31</td>
<td>Lung</td>
<td>$8,850,000</td>
</tr>
<tr>
<td>26</td>
<td>GI</td>
<td>$3,776,562</td>
</tr>
<tr>
<td>24</td>
<td>Prostate</td>
<td>$4,410,000</td>
</tr>
<tr>
<td>17</td>
<td>Melanoma</td>
<td>$6,250,000</td>
</tr>
<tr>
<td>13</td>
<td>Pancreatic</td>
<td>$5,050,000</td>
</tr>
<tr>
<td>10</td>
<td>Pediatric</td>
<td>$13,159,000</td>
</tr>
<tr>
<td>10</td>
<td>Brain</td>
<td>$3,050,000</td>
</tr>
<tr>
<td>8</td>
<td>Gyn./Cervical/Ovarian</td>
<td>$1,900,000</td>
</tr>
<tr>
<td>7</td>
<td>Renal</td>
<td>$2,686,500</td>
</tr>
<tr>
<td>6</td>
<td>Head and Neck</td>
<td>$1,350,000</td>
</tr>
<tr>
<td>6</td>
<td>Myeloma</td>
<td>$500,000</td>
</tr>
<tr>
<td>5</td>
<td>Ewings</td>
<td>$775,000</td>
</tr>
<tr>
<td>3</td>
<td>Colon</td>
<td>$350,000</td>
</tr>
<tr>
<td>496</td>
<td>Total</td>
<td>$101,391,054</td>
</tr>
</tbody>
</table>

### TOP 15 GRANT DISTRIBUTIONS BY STATE, 1994-2012

<table>
<thead>
<tr>
<th>State</th>
<th>Funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>CA</td>
<td>$20,296,312</td>
</tr>
<tr>
<td>NC</td>
<td>$11,170,954</td>
</tr>
<tr>
<td>MA</td>
<td>$10,900,000</td>
</tr>
<tr>
<td>TX</td>
<td>$7,684,697</td>
</tr>
<tr>
<td>FL</td>
<td>$7,661,860</td>
</tr>
<tr>
<td>NY</td>
<td>$6,179,861</td>
</tr>
<tr>
<td>PA</td>
<td>$5,456,709</td>
</tr>
<tr>
<td>MD</td>
<td>$4,956,200</td>
</tr>
<tr>
<td>OH</td>
<td>$3,852,017</td>
</tr>
<tr>
<td>TN</td>
<td>$3,000,000</td>
</tr>
<tr>
<td>IL</td>
<td>$2,505,750</td>
</tr>
<tr>
<td>VA</td>
<td>$2,202,650</td>
</tr>
<tr>
<td>MN</td>
<td>$1,804,322</td>
</tr>
<tr>
<td>IN</td>
<td>$1,729,175</td>
</tr>
<tr>
<td>NJ</td>
<td>$1,450,000</td>
</tr>
</tbody>
</table>